RSV immunization in adults and children: A practical guide for clinicians

Cleve Clin J Med. 2024 Sep 4;91(9 suppl 1):S11-S18. doi: 10.3949/ccjm.91.s1.03.

Abstract

In 2023 and 2024, 3 vaccines were approved by the US Food and Drug Administration (FDA) against respiratory syncytial virus (RSV) in adults. In addition, the first long-acting RSV monoclonal antibody for infants and young children was approved. This review provides clinicians with practical guidance to navigate this new era of RSV prevention.

Publication types

  • Review

MeSH terms

  • Adult
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Practice Guidelines as Topic
  • Respiratory Syncytial Virus Infections* / prevention & control
  • Respiratory Syncytial Virus Vaccines* / immunology
  • United States

Substances

  • Respiratory Syncytial Virus Vaccines